NO971997D0 - Bruk av immunmodulerende midler - Google Patents

Bruk av immunmodulerende midler

Info

Publication number
NO971997D0
NO971997D0 NO971997A NO971997A NO971997D0 NO 971997 D0 NO971997 D0 NO 971997D0 NO 971997 A NO971997 A NO 971997A NO 971997 A NO971997 A NO 971997A NO 971997 D0 NO971997 D0 NO 971997D0
Authority
NO
Norway
Prior art keywords
immunomodulatory agents
pka
well
pharmaceutical compositions
protein kinase
Prior art date
Application number
NO971997A
Other languages
English (en)
Norwegian (no)
Inventor
Kjetil Tasken
Einar Martin Aandahl
Paal Aukrust
Bjoern S Skaalhegg
Fredrik Mueller
Stig Froeland
Vidar Hansson
Original Assignee
Kjetil Tasken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kjetil Tasken filed Critical Kjetil Tasken
Priority to NO971997A priority Critical patent/NO971997D0/no
Publication of NO971997D0 publication Critical patent/NO971997D0/no
Priority to JP54685698A priority patent/JP2002501499A/ja
Priority to DE69804125T priority patent/DE69804125T2/de
Priority to AU70865/98A priority patent/AU738674B2/en
Priority to EP98917808A priority patent/EP1024809B1/de
Priority to DK98917808T priority patent/DK1024809T3/da
Priority to AT98917808T priority patent/ATE213944T1/de
Priority to CA002288215A priority patent/CA2288215C/en
Priority to NZ501181A priority patent/NZ501181A/en
Priority to ES98917808T priority patent/ES2171018T3/es
Priority to PT98917808T priority patent/PT1024809E/pt
Priority to PCT/NO1998/000134 priority patent/WO1998048809A1/en
Priority to NO19995269A priority patent/NO325209B1/no
Priority to US11/136,560 priority patent/US20050250727A1/en
Priority to JP2009295046A priority patent/JP2010111688A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
NO971997A 1997-04-29 1997-04-29 Bruk av immunmodulerende midler NO971997D0 (no)

Priority Applications (15)

Application Number Priority Date Filing Date Title
NO971997A NO971997D0 (no) 1997-04-29 1997-04-29 Bruk av immunmodulerende midler
PCT/NO1998/000134 WO1998048809A1 (en) 1997-04-29 1998-04-29 Use of immunomodulating agents
AT98917808T ATE213944T1 (de) 1997-04-29 1998-04-29 Verwendung von immunomodulatoren
NZ501181A NZ501181A (en) 1997-04-29 1998-04-29 Use of inhibitors selected from cAMP antagonists, hammerhead ribozymes, sequence specific antisense oligonucleotides and anchoring disruption peptides for treating immunosuppressive diseases
AU70865/98A AU738674B2 (en) 1997-04-29 1998-04-29 Use of immunomodulating agents
EP98917808A EP1024809B1 (de) 1997-04-29 1998-04-29 Verwendung von immunomodulatoren
DK98917808T DK1024809T3 (da) 1997-04-29 1998-04-29 Anvendelse af immunomodulatorer
JP54685698A JP2002501499A (ja) 1997-04-29 1998-04-29 免疫調節剤の用途
CA002288215A CA2288215C (en) 1997-04-29 1998-04-29 Use of immunomodulating agents
DE69804125T DE69804125T2 (de) 1997-04-29 1998-04-29 Verwendung von immunomodulatoren
ES98917808T ES2171018T3 (es) 1997-04-29 1998-04-29 Uso de agentes inmunomoduladores.
PT98917808T PT1024809E (pt) 1997-04-29 1998-04-29 Utilizacao de agentes de imunomodulacao
NO19995269A NO325209B1 (no) 1997-04-29 1999-10-28 Anvendelse av immunmodulerende midler, peptid, hammerhoderibozymer, antisensoligonukleotider, farmasoytiske blandinger og inhibitorer.
US11/136,560 US20050250727A1 (en) 1997-04-29 2005-05-25 Use of immunomodulating agents
JP2009295046A JP2010111688A (ja) 1997-04-29 2009-12-25 免疫調節剤の用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO971997A NO971997D0 (no) 1997-04-29 1997-04-29 Bruk av immunmodulerende midler

Publications (1)

Publication Number Publication Date
NO971997D0 true NO971997D0 (no) 1997-04-29

Family

ID=19900676

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971997A NO971997D0 (no) 1997-04-29 1997-04-29 Bruk av immunmodulerende midler

Country Status (13)

Country Link
US (1) US20050250727A1 (de)
EP (1) EP1024809B1 (de)
JP (2) JP2002501499A (de)
AT (1) ATE213944T1 (de)
AU (1) AU738674B2 (de)
CA (1) CA2288215C (de)
DE (1) DE69804125T2 (de)
DK (1) DK1024809T3 (de)
ES (1) ES2171018T3 (de)
NO (1) NO971997D0 (de)
NZ (1) NZ501181A (de)
PT (1) PT1024809E (de)
WO (1) WO1998048809A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ508359A (en) * 1998-05-27 2003-07-25 Lauras As Method of altering the activity of proteins of the PKA signalling pathway
EP1147413B1 (de) * 1999-01-21 2006-04-05 Metamorphix, Inc. Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
AU2080001A (en) * 1999-12-07 2001-06-18 University Of Medicine And Dentistry Of New Jersey Nucleic acid and protein expressed thereby and their involvement in stress
US6958214B2 (en) * 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
AU2003228809A1 (en) 2002-05-03 2003-11-17 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
WO2005060996A2 (en) * 2003-12-23 2005-07-07 Lauras As Method of altering the pka type i signalling pathway
GB0413726D0 (en) 2004-06-18 2004-07-21 Lauras As Compounds
GB0421355D0 (en) * 2004-09-24 2004-10-27 Univ Oslo Inhibitors
GB0518027D0 (en) * 2005-09-05 2005-10-12 Birkeland Innovasjon As Compounds
GB0618235D0 (en) 2006-09-15 2006-10-25 Lauras As Process
CN113648323A (zh) 2013-06-05 2021-11-16 再生疗法有限公司 用于哺乳动物物种中诱导性组织再生的组合物和方法
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
US10240127B2 (en) * 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
EP3387112A4 (de) 2015-12-07 2019-08-21 BioTime, Inc. Verfahren zur erneuten gewinnung von brauen fettzellen, die aus verschiedenen pluripotenten stammzellen gewonnen werden
US20230285556A1 (en) * 2021-09-13 2023-09-14 Omeros Corporation Methods and compositions for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568676A (en) * 1983-11-25 1986-02-04 Thomas Jefferson University Method of inhibiting aggregation using thromboxane synthetase inhibitor in combination with a cyclic AMP phosphodiesterase inhibitor
US5276017A (en) * 1990-09-14 1994-01-04 Trustees Of The University Of Pennsylvania Therapeutic and diagnostic applications of tropho-uteronectin (TUN) manipulation
US6429208B1 (en) * 1992-03-27 2002-08-06 Regents Of The University Of California Methods and compositions for restoring impaired cellular immune function
WO1993021929A1 (en) * 1992-05-01 1993-11-11 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Phosphorothioate derivatives of cyclic amp analogues
ATE312188T1 (de) * 1993-01-22 2005-12-15 Univ Research Corp Lokalisierung von therapeutischen mitteln
US5807693A (en) * 1994-11-23 1998-09-15 Icos Corporation Calcineurin inhibitory compounds and anchoring protein
US5795735A (en) * 1995-07-17 1998-08-18 Icos Corporation Isolated polynucleotides encoding PKA-binding proteins and methods of producing the proteins recombinantly
US5969117A (en) * 1995-08-17 1999-10-19 Hybridon, Inc. Modified protein kinase a-specific oligonucleotide

Also Published As

Publication number Publication date
JP2002501499A (ja) 2002-01-15
DE69804125T2 (de) 2002-10-31
ATE213944T1 (de) 2002-03-15
PT1024809E (pt) 2002-07-31
EP1024809A1 (de) 2000-08-09
CA2288215A1 (en) 1998-11-05
DK1024809T3 (da) 2002-06-24
NZ501181A (en) 2002-03-01
AU7086598A (en) 1998-11-24
CA2288215C (en) 2009-08-18
ES2171018T3 (es) 2002-08-16
US20050250727A1 (en) 2005-11-10
WO1998048809A1 (en) 1998-11-05
DE69804125D1 (de) 2002-04-11
JP2010111688A (ja) 2010-05-20
EP1024809B1 (de) 2002-03-06
AU738674B2 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
ZA981627B (en) Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
CA2137203A1 (en) Protein kinase c inhibitors
FR2696094B1 (fr) Nouvelles compositions pharmaceutiques contenant des cyclosporines.
EA200200571A1 (ru) Новая композиция и ее применение
DK0807111T3 (da) Substituerede heterocykliske forbindelser, fremgangsmåde til fremstillingen heraf samt farmaceutiske sammensætninger indeholdende disse
NO971997D0 (no) Bruk av immunmodulerende midler
ITRM960810A0 (it) Composizioni farmaceutiche contenenti ciclosporine o macrolidi
HUP0103617A2 (hu) Protein kinázt gátló, pirrolilcsoporttal helyettesített 2-indolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
EA199900373A2 (ru) Фармацевтические композиции
DK1200418T3 (da) Nematodicide trifluorbutener
DK1140993T3 (da) Glycopeptidderivater og farmaceutiske præparater indeholdende dem
DZ2494A1 (fr) Composition pharmaceutique d'oméprazole.
DK0747050T4 (da) Farmaceutiske sammensætninger, der indeholder irbesartan
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TR199800011T1 (xx) Benzo$g] kuinolin t�revleri
BR9714358A (pt) Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
SE9604348D0 (sv) Användning av hydroxyguanidiner
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
DK0838469T3 (da) 10,13,15-trioxatricyclo(9.2.1 9.6)-pentadecanon-derivater, fremgangsmåde til deres fremstilling og lægemidler indeholdende disse forbindelser
BR9605046B1 (pt) compostos n-(pirimidinl)-benzenossulfonamida e preparação farmacêutica contendo as mesmas.
KR970061248A (ko) 알츠하이머병 치료용 1, 1, 2-트리페닐부트-1-엔 유도체
TR199800152T1 (xx) Endotelin Resept�r Antagonistleri
NO20020914L (no) Alkoksy-substituerte benzimidazolforbindelser, preparater inneholdende slike samt anvendelser derav